Indications for: NAMENDA XR
Moderate-to-severe dementia of the Alzheimer's type.
Do not divide doses. Swallow whole or may open caps and sprinkle on applesauce, then consume entire contents. Initially 7mg once daily; titrate at intervals of at least 1 week in increments of 7mg to target dose of 28mg once daily. Max 28mg once daily. Severe renal impairment (CrCl 5–29mL/min): titrate to target dose of 14mg/day. Switching from immediate-release tabs: give XR caps the day after last dose of immediate-release tabs; see full labeling.
NAMENDA XR Warnings/Precautions:
Severe hepatic impairment. Alkalinized urine (eg, renal tubular acidosis, severe UTI) increases memantine serum levels. Seizure disorder. Pregnancy. Nursing mothers.
NAMENDA XR Classification:
NMDA receptor antagonist.
NAMENDA XR Interactions:
Caution with other NMDA antagonists (eg, amantadine, ketamine, dextromethorphan). May affect or be affected by renally-excreted drugs (eg, triamterene, HCTZ, metformin, cimetidine, nicotine, ranitidine, quinidine). Plasma levels may be increased by urinary alkalinizers.
Headache, dizziness, confusion, diarrhea, constipation, hypertension, pain, somnolence, hallucination, urinary disorders, dyspnea.
Renal. Half-life: ~60–80 hours.
Generic Drug Availability:
Tabs—60; Titration Pak (28 x 5mg + 21 x 10mg)—1; Oral soln—contact supplier; XR caps 7mg, 21mg—30; 14mg, 28mg—30, 90; XR Titration Pak (7 x 7mg + 7 x 14mg + 7 x 21mg + 7 x 28mg)—1